Skip to main content
. 2020 Jan 15;14(2):158–167. doi: 10.1007/s11764-019-00839-w

Table 2.

Diagnosis and treatment characteristics at baseline (n = 330) stratified by treatment type

Total (n = 330) Locoregional treatment (n = 100) Chemotherapy (n = 194) Other systemic therapy (n = 30)
Tumor diagnosis, n (%)
  Breast cancer 156 (47.3) 23 (23.0) 115 (59.3) 17 (56.7)
  Male reproductive cancers 34 (10.3) 18 (18.0) 6 (3.1) 9 (30.0)
  Hematologic cancer 30 (9.1) 1 (1.0) 25 (12.9) 1 (3.3)
  Gastrointestinal cancer 26 (7.9) 8 (8.0) 16 (8.2) 1 (3.3)
  Colon cancer 23 (7.0) 9 (9.0) 14 (7.2)
  Skin cancer 13 (3.9) 13 (13.0)
  Gynecological cancer 11 (3.3) 4 (4.0) 7 (3.6)
  Head and neck cancer 10 (3.0) 8 (8.0) 1 (0.5) 1 (3.3)
  Lung cancer 10 (3.0) 1 (1.0) 8 (4.1) 1 (3.3)
  Urological cancer 10 (3.0) 10 (10.0)
  Endocrine cancer 3 (0.9) 3 (3.0)
  Bone cartilage and soft tissue cancer 2 (0.6) 1 (1.0) 1 (0.5)
  Central nervous system cancer 1 (0.3) 1 (0.5)
  Eye cancer 1 (0.3) 1 (1.0)
Extent of disease, n (%)
  Local 109 (33.0) 48 (48.0) 49 (25.3) 12 (40.0)
  Reginal 93 (28.2) 14 (14.0) 75 (38.7) 4 (13.3)
  Distant 10 (3.0) 7 (3.6) 3 (10.0)
  Unknown 118 (35.8) 38 (38.0) 63 (32.5) 11 (36.7)
Treatment completed, n (%)
  Yes 208 (63.2) 94 (94.9) 104 (53.6) 7 (23.3)
  No 121 (36.8) 5 (5.1) 90 (46.4) 23 (76.7)
Time diagnosis to RTW, a M ± SD 7.4 ± 6.4 5.6 ± 7.4 8.6 ± 5.5 4.5 ± 5.4
Memory symptoms,1 M ± SD 32.1 ± 19.6 32.6 ± 18.9 31.7 ± 20.1 35.9 ± 18.7
Executive function symptoms,2 M ± SD 19.3 ± 15.9 20.4 ± 14.9 18.0 ± 16.0 24.8 ± 17.5
Depressive symptoms, M ± SD 4.6 ± 3.6 5.0 ± 3.9 4.3 ± 3.3 5.3 ± 4.1
Fatigue, M ± SD 30.1 ± 11.4 30.6 ± 11.7 29.3 ± 11.2 33.6 ± 10.7

Note: M, mean; SD, standard deviation;. 1For the comparison between treatment types p = 0.564; 2 For the comparison between treatment types p = 0.083